Baird Medical Concludes Successful Participation at ACS Clinical Congress 2025 with Strong Interest in MWA Technology

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) concluded participation at the ACS Clinical Congress 2025 (October 5–7), showcasing its minimally invasive microwave ablation (MWA) systems to a global surgical audience.

At the exhibit, the company's advanced MWA technology drew significant surgeon interest across specialties, with live demonstrations focused on applications for thyroid nodules, breast disease, and other conditions. The company reported high engagement and renewed discussions with surgical and interventional leaders from leading institutions, and said it will pursue expanded U.S. and international partnerships building on congress momentum.

News Market Reaction

+0.63%

2 alerts

+0.63% News Effect

-2.3% Trough Tracked

+$389K Valuation Impact

$62M Market Cap

0.1x Rel. Volume

On the day this news was published, BDMD gained 0.63%, reflecting a mild positive market reaction. Argus tracked a trough of -2.3% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $389K to the company's valuation, bringing the market cap to $62M at that time.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, has successfully concluded its participation in the American College of Surgeons (ACS) Clinical Congress 2025, held from October 5-7. The event served as a key platform for showcasing the Company's innovative technology to a global surgical audience.

At its exhibit, Baird Medical's advanced MWA systems drew significant interest from surgeons across multiple specialties. The live demonstrations were a major highlight, allowing attendees to gain hands-on experience with the technology's applications for thyroid nodules, breast disease, and other conditions. The positive reception and high level of engagement from surgeons underscored the growing demand for effective, minimally invasive treatment options.

A key success of the event was the opportunity to reconnect with prominent leaders in surgery and interventional medicine from top institutions. These collaborative discussions reinforced Baird Medical's mission to enhance patient care through technological innovation. Building on the momentum from the congress, the Company reaffirms its commitment to expanding its presence and partnerships within the U.S. and international markets.

About the ACS Clinical Congress

The American College of Surgeons (ACS) Clinical Congress is one of the world's largest gatherings of surgeons, dedicated to sharing advancements in surgical techniques and improving patient care. The congress brings together thousands of professionals from across the globe to exchange knowledge and foster collaborations that advance clinical practices.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-concludes-successful-participation-at-acs-clinical-congress-2025-with-strong-interest-in-mwa-technology-302575471.html

SOURCE BDMD

FAQ

When did Baird Medical (BDMD) participate in ACS Clinical Congress 2025?

Baird Medical exhibited at ACS Clinical Congress 2025 from October 5–7, 2025.

What BDMD technology was showcased at ACS Clinical Congress 2025?

Baird Medical showcased its microwave ablation (MWA) systems with live demonstrations.

Which clinical applications did BDMD demonstrate at the congress?

Live demonstrations highlighted MWA applications for thyroid nodules, breast disease, and other surgical uses.

Did BDMD report surgeon interest at ACS Clinical Congress 2025?

Yes. The company reported significant interest and high engagement from surgeons across multiple specialties.

How will BDMD use the outcomes from ACS Clinical Congress 2025?

BDMD said it will build on congress momentum to expand U.S. and international partnerships and reconnect with clinical leaders.

Where can investors find more information about BDMD’s clinical outreach after the event?

Investors can monitor Baird Medical’s investor communications and filings for updates on partnerships and market expansion initiatives.